Literature DB >> 21574642

Efficient orthogonal bioconjugation of dendrimers for synthesis of bioactive nanoparticles.

Hubert F Gaertner1, Fabrice Cerini, Arun Kamath, Anne-Françoise Rochat, Claire-Anne Siegrist, Laure Menin, Oliver Hartley.   

Abstract

Nanoparticles carrying biologically active functional sets (e.g., targeting moiety, payload, tracer) have potential use in a wide range of clinical applications. Though complex, such constructions should, as far as possible, have a defined molecular architecture and be monodisperse. However, the existing methods to achieve this goal are unsuitable for the incorporation of peptides and proteins, and those that provide for orthogonal introduction of two different types of functional element are incompatible with the use of commercially available materials. In this study, we have developed approaches for the production of nanoparticles based on commercially available polyamidoamine (PAMAM) dendrimers. First, we identified an optimized oxime conjugation strategy under which complex dendrimers can be fully decorated not only with model peptides, but also with recombinant proteins (insulin was taken as an example). Second, we developed a strategy based on a two-chain covalent heterodendrimer (a "diblock") based on cystamine core PAMAM dendrimers and used it to generate heterodendrimers, into which a peptide array and a mannose array were orthogonally introduced. Finally, by incorporating a functionalized linker into the diblock architecture we were able to site-specifically introduce a third functional element into the nanoparticle. We exemplified this approach using fluorescein, a mannose array, and a peptide array as the three functionalities. We showed that incorporation of a mannose array into a nanoparticle strongly and specifically enhances uptake by sentinel cells of the immune system, an important property for vaccine delivery applications. These PAMAM dendrimer-based approaches represent a robust and versatile platform for the development of bioactive nanoparticles.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21574642     DOI: 10.1021/bc1005653

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  7 in total

1.  Fluorine-Containing Taxoid Anticancer Agents and Their Tumor-Targeted Drug Delivery.

Authors:  Joshua Seitz; Jacob G Vineberg; Edison S Zuniga; Iwao Ojima
Journal:  J Fluor Chem       Date:  2013-08-01       Impact factor: 2.050

2.  Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.

Authors:  Ingrid S Ganda; Qian Zhong; Mirabela Hali; Ricardo L C Albuquerque; Francine F Padilha; Sandro R P da Rocha; Judith A Whittum-Hudson
Journal:  Int J Pharm       Date:  2017-05-22       Impact factor: 5.875

3.  Exploration of fluorine chemistry at the multidisciplinary interface of chemistry and biology.

Authors:  Iwao Ojima
Journal:  J Org Chem       Date:  2013-05-06       Impact factor: 4.354

4.  Flexible synthesis of cationic peptide-porphyrin derivatives for light-triggered drug delivery and photodynamic therapy.

Authors:  R Dondi; E Yaghini; K M Tewari; L Wang; F Giuntini; M Loizidou; A J MacRobert; I M Eggleston
Journal:  Org Biomol Chem       Date:  2016-12-07       Impact factor: 3.876

5.  Design, Synthesis, and Biological Evaluations of Asymmetric Bow-Tie PAMAM Dendrimer-Based Conjugates for Tumor-Targeted Drug Delivery.

Authors:  Tao Wang; Yaozhong Zhang; Longfei Wei; Yuhan G Teng; Tadashi Honda; Iwao Ojima
Journal:  ACS Omega       Date:  2018-04-03

Review 6.  Peptide Vaccine: Progress and Challenges.

Authors:  Weidang Li; Medha D Joshi; Smita Singhania; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Vaccines (Basel)       Date:  2014-07-02

7.  (64)Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque.

Authors:  Jai Woong Seo; Hyounggee Baek; Lisa M Mahakian; Jiro Kusunose; Juliana Hamzah; Erkki Ruoslahti; Katherine W Ferrara
Journal:  Bioconjug Chem       Date:  2014-01-31       Impact factor: 4.774

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.